Nafarelin in the management of endometriosis: quality of life assessment.

Article Details

Citation
Copy to clipboard

Burry KA

Nafarelin in the management of endometriosis: quality of life assessment.

Am J Obstet Gynecol. 1992 Feb;166(2):735-9.

PubMed ID
1531576 [ View in PubMed
]
Abstract

Quality of life is important when comparing the relative advantages of nafarelin versus danazol for the treatment of endometriosis. Recent studies have investigated the potential differences between the safety profiles of nafarelin and danazol and the impact of these profiles on the patient's quality of life. Results show that although these drugs have similar efficacy, they are associated with very different safety profiles. Most notable are the androgenic effects such as weight gain associated with danazol. With nafarelin, hypoestrogenic side effects, such as hot flashes, are more common. More important, these differences in safety profiles may prove to be relevant to patient satisfaction and compliance with therapy.

DrugBank Data that Cites this Article

Drugs